Floatz Rating
C34/100
Confidence
Indicative
Sponsor
Shanghai Fengxian District Central Hospital
Modality
gene_therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05180851CT.gov Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant L-Ifn Adenovirus (this asset) | Shanghai Fengxian District Central Hospital | Early P1 | C · 34 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Ipilimumab | M.D. Anderson Cancer Center | P4 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
| Sargramostim | Mayo Clinic | P3 | BB |
| Pembrolizumab | Biocon Biologics UK PLC | P4 | BB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
+42 more in the Melanoma cohort
Other indications for Recombinant L-Ifn Adenovirus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glioblastoma | — | Early P1 | C · 39 |
| Cervical Carcinoma | — | Early P1 | C · 39 |
| Ovarian Carcinoma | — | Early P1 | C · 38 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant L-Ifn Adenovirus in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-l-ifn-adenovirus-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →